Jan. 30, 2024
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Zonisamide is chemically classified as a sulfonamide and is unrelated to other antiepileptic drugs. Originally developed in Japan for the treatment of epilepsy, it was later approved in 1989, and has since been licensed in many countries. It was under investigation for cerebral ischemia, but no development has been reported for this indication since 1994. Zonisamide was approved by the Food and Drug Administration in 2000 for marketing as an add-on adult focal epilepsy treatment. It is now approved in Europe as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy.
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.